Epoprostenol vs Treprostinil (Tyvaso)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Epoprostenol · Flolan

Rights held by GlaxoSmithKline; US product discontinued

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Treprostinil (Tyvaso)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00147199 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).

Next expected readout: December 2027 · NCT07177703 (registry estimate)

Reported efficacy

Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)

Result source: NCT00147199

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Epoprostenol: 4 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEpoprostenolTreprostinil (Tyvaso)
6MWD - Change
absolute change · m
No placebo or comparator arm
-3.55 m @ 4wka,b,c
NCT01462565 · Phase 4 · registry result, not featured evidence
20 m @ 12wka,b,c
NCT01268553 · Phase 4 · registry result, not featured evidence
1 other source trial
230 m @ 12wk
NCT00705133 · Phase 2 · registry result, not featured evidence
Dropout rate
0%d
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
10%
NCT01105091 · Phase 4 · registry result, not featured evidence
11.3%e
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
11%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—d
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT01105117 · Phase 4 · registry result, not featured evidence
—
NCT01105091 · Phase 4 · registry result, not featured evidence
—e
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
—
NCT01268553 · Phase 4 · registry result, not featured evidence
4.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
—
NCT00705133 · Phase 2 · registry result, not featured evidence
Serious AEs
12.5%d
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
30%
NCT01105091 · Phase 4 · registry result, not featured evidence
7.8%e
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
13.7%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
d
diarrhoea 12.5%
fatigue 12.5%
headache 12.5%
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
catheter site erythema 100%
flushing 0%
NCT01105117 · Phase 4 · registry result, not featured evidence
pain in jaw 75%
headache 65%
nausea 50%
NCT01105091 · Phase 4 · registry result, not featured evidence
e
cough 53.9% (placebo 29.2%)
headache 40.9% (placebo 22.5%)
nausea 19.1% (placebo 10.8%)
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 2 more results
cough 74%
headache 43.8%
nausea 30.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
general prostacyclin adverse reaction profile 100%
NCT00705133 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: registered conditions differ.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 12 weeks versus 4 weeks.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Epoprostenol

SF-36 Physical Functioning -1.156 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Physical -0.765 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Physical
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Emotional 0.002 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Emotional
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Vitality 0.781 score @ 4wk
absolute change · score
No placebo or comparator arm
Vitality
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Social Functioning 1.706 score @ 4wk
absolute change · score
No placebo or comparator arm
Social Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Bodily Pain 3.065 score @ 4wk
absolute change · score
No placebo or comparator arm
Bodily Pain
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 General Health -0.606 score @ 4wk
absolute change · score
No placebo or comparator arm
General Health
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Physical Component Summary -0.123 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Health Component
NCT01462565 · Phase 4 · registry result, not featured evidence
Borg Dyspnea 0.36 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT01462565 · Phase 4 · registry result, not featured evidence
6MWD - Change 288 vs 323.5 Epoprostenol Sodium for Injection m @ 4wk
absolute change · m
NCT01105091 · Phase 4 · registry result, not featured evidence
SvO2 58% (n=11) vs 56% (n=6) Epoprostenol Sodium for Injection @ 4wk
absolute change · percentage points
NCT01105091 · Phase 4 · registry result, not featured evidence

Treprostinil (Tyvaso)

Six Minute Walk Distance Peak Change 21.6 vs 3 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
21.6 vs 3 placebo m @ 6wk
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening 4 vs 6 placebo count @ 12wk
event rate · count
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Distance Trough Change 12.4 vs 0.8 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Mlwhf Total -3 vs 0 placebo score @ 12wk
absolute change · score
Global Score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Signs and Symptoms 0 vs 0 placebo score @ 12wk
absolute change · score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening Free 100% (n=6) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
Ventilatory Efficiency Change Slope 1.2 ratio @ 12wk
ratio to baseline · ratio
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
CAMPHOR -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
6MWD - Change 16 m @ 12wk
absolute change · m
No placebo or comparator arm
Change from Baseline
NCT00741819 · Phase 4 · registry result, not featured evidence
QOL -2.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Quality of Life Score
NCT00741819 · Phase 4 · registry result, not featured evidence
CAMPHOR -6.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Total Score
NCT00741819 · Phase 4 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Epoprostenol's landscape · Treprostinil (Tyvaso)'s landscape